Genflow Biosciences PLC Announces Company Update on Dog Trials
Genflow Biosciences (OTCQB:GENFF), Europe's only public longevity company, has reported positive progress in its Dog Aging study (GF-1004), testing a novel SIRT6-centenarian gene therapy. The trial involves 28 beagles aged 10+ years, with treatment administered in March 2025 showing no adverse effects.
The study aims to evaluate the therapy's potential in extending lifespan and improving quality of life in companion animals. Key objectives include validating safety, demonstrating benefits like reduced biological age, increased muscle strength, enhanced mitochondrial function, and improved coat quality. The five-month follow-up period will conclude in January 2026.
The successful completion of this trial could lead to a licensing agreement with a major Animal Health company and potentially unlock future applications in human longevity therapeutics.
Genflow Biosciences (OTCQB:GENFF), unica società europea quotata nel settore della longevità, ha comunicato progressi positivi nello studio su cani (GF-1004) che testa una nuova terapia genica SIRT6 ispirata ai centenari. Il trial coinvolge 28 beagle di età superiore ai 10 anni; il trattamento somministrato a marzo 2025 non ha evidenziato effetti avversi.
Lo studio valuta la capacità della terapia di prolungare la durata della vita e migliorare la qualità di vita degli animali da compagnia. Gli obiettivi principali sono confermare la sicurezza e dimostrare benefici quali riduzione dell’età biologica, aumento della forza muscolare, miglior funzionamento mitocondriale e qualità del mantello. Il follow-up di cinque mesi si concluderà a gennaio 2026.
Il completamento positivo del trial potrebbe portare a un accordo di licenza con una grande azienda di Animal Health e aprire la strada a future applicazioni nella longevità umana.
Genflow Biosciences (OTCQB:GENFF), la única compañía europea cotizada dedicada a la longevidad, ha anunciado avances positivos en su estudio en perros (GF-1004) que prueba una nueva terapia génica SIRT6 basada en centenarios. El ensayo incluye a 28 beagles de más de 10 años; el tratamiento administrado en marzo de 2025 no mostró efectos adversos.
El estudio pretende evaluar si la terapia puede extender la vida y mejorar la calidad de vida de animales de compañía. Los objetivos clave son validar la seguridad y demostrar beneficios como reducción de la edad biológica, mayor fuerza muscular, mejora de la función mitocondrial y mejor aspecto del pelaje. El seguimiento de cinco meses finalizará en enero de 2026.
La finalización exitosa del ensayo podría conducir a un acuerdo de licencia con una gran compañía de Animal Health y abrir posibilidades para aplicaciones futuras en terapias de longevidad humana.
Genflow Biosciences (OTCQB:GENFF), 유럽에서 유일한 상장된 장수(롱제비티) 기업은 새로운 SIRT6 센테나리언 유전자치료를 시험하는 개 대상 연구(GF-1004)에서 긍정적 진전을 보고했습니다. 해당 임상에는 10세 이상 비글 28마리가 포함되며, 2025년 3월에 투여된 치료는 이상반응이 없었습니다.
이 연구는 반려동물의 기대수명 연장 및 삶의 질 개선 가능성을 평가하는 것을 목표로 합니다. 주요 목표는 안전성 검증과 생물학적 연령 감소, 근력 향상, 미토콘드리아 기능 개선, 털 상태 개선 같은 이점 입증입니다. 5개월 추적 관찰은 2026년 1월에 종료됩니다.
본 임상이 성공적으로 마무리되면 주요 애니멀헬스 기업과의 라이선스 계약으로 이어질 수 있으며, 향후 인간 대상 장수 치료제 개발의 가능성을 열어줄 수 있습니다.
Genflow Biosciences (OTCQB:GENFF), la seule société publique de longévité en Europe, a annoncé des progrès positifs dans son étude canine (GF-1004) testant une nouvelle thérapie génique SIRT6 inspirée des centenaires. L'essai porte sur 28 beagles âgés de plus de 10 ans ; le traitement administré en mars 2025 n'a révélé aucun effet indésirable.
L'étude vise à évaluer le potentiel de la thérapie pour prolonger la durée de vie et améliorer la qualité de vie des animaux de compagnie. Les objectifs clés sont de valider la sécurité et de démontrer des bénéfices tels que la réduction de l'âge biologique, l'augmentation de la force musculaire, l'amélioration de la fonction mitochondriale et la qualité du pelage. Le suivi de cinq mois se terminera en janvier 2026.
La réussite de cet essai pourrait déboucher sur un accord de licence avec une grande entreprise d'Animal Health et ouvrir la voie à des applications futures dans les thérapeutiques de longévité humaine.
Genflow Biosciences (OTCQB:GENFF), das einzige börsennotierte Longevity-Unternehmen Europas, meldet positive Fortschritte in der Hunde-Studie (GF-1004), in der eine neuartige SIRT6-Centenarian-Gen-Therapie getestet wird. An der Studie nehmen 28 Beagles im Alter von über 10 Jahren teil; die im März 2025 verabreichte Behandlung zeigte keine Nebenwirkungen.
Ziel der Studie ist es, das Potenzial der Therapie zur Lebensverlängerung und Verbesserung der Lebensqualität von Haustieren zu untersuchen. Wichtige Ziele sind die Bestätigung der Sicherheit sowie der Nachweis von Vorteilen wie verringerte biologische Alterung, erhöhte Muskelkraft, verbesserte mitochondriale Funktion und eine bessere Fellqualität. Die fünfmonatige Nachbeobachtung endet im Januar 2026.
Ein erfolgreicher Abschluss des Trials könnte zu einer Lizenzvereinbarung mit einem großen Animal-Health-Unternehmen führen und mögliche Anwendungen in der menschlichen Longevity-Therapie eröffnen.
- None.
- Results of therapy effectiveness not yet available
- Five-month follow-up period required before conclusive results
Genflow Advances World's First Longevity Gene Therapy Trial in Dogs with No Adverse Effects Reported
LONDON, UK / ACCESS Newswire / August 18, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, provides an update on its Dog Aging (GF-1004) study, a proof-of-concept clinical trial evaluating the safety and efficacy of its proprietary SIRT6-centenarian gene therapy for age-related decline in elderly dogs.
The randomized, controlled trial, conducted with CRO Syngene, involves 28 beagles aged 10+ years. In March, recipients received three different modalities of SIRT6 gene therapy with no ill or adverse effects, while controls remain untreated. The dogs will now enter a five-month follow-up period expected to conclude in January 2026.
The strategic goal of this proof-of-concept trial is to generate compelling preclinical data that will enable a licensing agreement with a leading Animal Health company. GF-1004 is a first-in-class gene therapy candidate targeting fundamental aging mechanisms shared by both dogs and humans. By intervening at the mitochondrial and epigenetic levels, GF-1004 offers the potential to not only extend lifespan, but also improve the quality of life in companion animals, a rapidly growing, high-value market segment.
Study objectives are to:
1. Confirm feasibility of GF-1004 administration in the target population.
2. Validate safety and efficacy at the proposed administered dose.
3. Demonstrate multi-dimensional benefits relevant to both clinical outcomes and consumer appeal, including:
Reduced biological age (GRIM methylation clock)
Increased muscle strength and mass
Enhanced mitochondrial function
Improved coat quality
Better overall health metrics
Translational Potential
Since dogs and humans share conserved aging pathways, success in this trial will provide a strong foundation for expansion into human health applications, unlocking additional markets in longevity therapeutics.
Dr. Eric Leire, CEO of Genflow, commented: "Now that all dogs have received the treatment without any adverse events, we've taken an important step in confirming the treatment's safety profile. We are fully focused on advancing GF-1004 to secure a partnership with an animal health company, combining scientific and commercial expertise to pave the way for a new class of therapeutic medicines for dogs. Our shared goal is to extend the healthspan of dogs, and we believe this study will demonstrate the safety and potential efficacy of GF-1004 while opening the door to broader applications of our proprietary platform in age-related diseases in both companion animals and, ultimately, in humans."
Contacts
Genflow Biosciences | Harbor Access |
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations |
+32-477-495-881 | +1 475 477 9401 |
Corporate Brokers | |
Capital Plus Partners Ltd | |
Jon Critchley, +44 207 432 0501 |
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned for 2025, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and X.
DISCLAIMER
The contents of this announcement have been prepared by, and are the sole responsibility of, the Company.
This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.
Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
FAQ
What is the status of Genflow Biosciences' (GENFF) dog aging trial in 2025?
How many dogs are involved in Genflow's GF-1004 clinical trial?
What are the main objectives of Genflow's dog aging study?
What is the potential market impact of Genflow's GF-1004 therapy?
When will Genflow's dog aging trial results be available?
